Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cocrystal Pharma, Inc. on May 30, 2017, reporting events occurring on that date. The filing primarily addresses a change in principal officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on executive compensation rather than financial performance.
Material Changes
On May 30, 2017, the Company entered into an agreement with James J. Martin to serve as Chief Financial Officer (CFO) on a full-time, non-interim basis, effective June 1, 2017. Mr. Martin had previously served as interim CFO as an independent contractor since February 27, 2017.
Management Commentary and Compensation
- Role: Chief Financial Officer (Full-time, non-interim).
- Start Date: June 1, 2017.
- Base Salary: $230,000 annually.
- Additional Compensation: Eligible for bonus compensation and equity awards at the discretion of the Board of Directors.
- Employment Status: At-will, pending negotiation of a formal employment agreement.
Investor Verification Checklist
- Verify the execution of the formal employment agreement between the Company and James J. Martin.
- Monitor future filings for details on specific bonus targets and equity award grants.
- Confirm the transition of duties from the interim contractor status to the full-time role.